Cost blocks public access to RSV protection for babies
High costs are preventing newly approved maternal vaccines and antibody treatments for RSV from entering South Africa's public healthcare system, leaving vulnerable infants without protection.
Read the full article
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on mg.co.za — the content belongs to Mail & Guardian.